|
1
|
Herbst RS, Fukuoka M and Baselga J:
Gefitinib - a novel targeted approach to treating cancer. Nat Rev
Cancer. 4:956–965. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carlin CR and Knowles BB: Identity of
human epidermal growth factor (EGF) receptor with glycoprotein
SA-7: evidence for differential phosphorylation of the two
components of the EGF receptor from A431 cells. Proc Natl Acad Sci
USA. 79:5026–5030. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Verveer PJ, Wouters FS, Reynolds AR and
Bastiaens PI: Quantitative imaging of lateral ErbB1 receptor signal
propagation in the plasma membrane. Science. 290:1567–1570. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lax I, Fischer R, Ng C, Segre J, Ullrich
A, Givol D and Schlessinger J: Noncontiguous regions in the
extracellular domain of EGF receptor define ligand-binding
specificity. Cell Regul. 2:337–345. 1991.PubMed/NCBI
|
|
8
|
Zhou M, Felder S, Rubinstein M, Hurwitz
DR, Ullrich A, Lax I and Schlessinger J: Real-time measurements of
kinetics of EGF binding to soluble EGF receptor monomers and dimers
support the dimerization model for receptor activation.
Biochemistry. 32:8193–8198. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sorokin A, Lemmon MA, Ullrich A and
Schlessinger J: Stabilization of an active dimeric form of the
epidermal growth factor receptor by introduction of an
inter-receptor disulfide bond. J Biol Chem. 269:9752–9759.
1994.PubMed/NCBI
|
|
10
|
Lemmon MA, Bu Z, Ladbury JE, et al: Two
EGF molecules contribute additively to stabilization of the EGFR
dimer. EMBO J. 16:281–294. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klein P, Mattoon D, Lemmon MA and
Schlessinger J: A structure-based model for ligand binding and
dimerization of EGF receptors. Proc Natl Acad Sci USA. 101:929–934.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dawson JP, Berger MB, Lin CC, Schlessinger
J, Lemmon MA and Ferguson KM: Epidermal growth factor receptor
dimerization and activation require ligand-induced conformational
changes in the dimer interface. Mol Cell Biol. 25:7734–7742. 2005.
View Article : Google Scholar
|
|
13
|
Burgess AW, Cho HS, Eigenbrot C, et al: An
open-and-shut case? Recent insights into the activation of EGF/ErbB
receptors. Mol Cell. 12:541–552. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang X, Gureasko J, Shen K, Cole PA and
Kuriyan J: An allosteric mechanism for activation of the kinase
domain of epidermal growth factor receptor. Cell. 125:1137–1149.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Pickin KA, Bose R, Jura N, Cole
PA and Kuriyan J: Inhibition of the EGF receptor by binding of MIG6
to an activating kinase domain interface. Nature. 450:741–744.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jura N, Endres NF, Engel K, et al:
Mechanism for activation of the EGF receptor catalytic domain by
the juxtamembrane segment. Cell. 137:1293–1307. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Honegger AM, Kris RM, Ullrich A and
Schlessinger J: Evidence that autophosphorylation of solubilized
receptors for epidermal growth factor is mediated by intermolecular
cross-phosphorylation. Proc Natl Acad Sci USA. 86:925–929. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Skolnik EY, Margolis B, Mohammadi M, et
al: Cloning of PI3 kinase-associated p85 utilizing a novel method
for expression/cloning of target proteins for receptor tyrosine
kinases. Cell. 65:83–90. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung
cancer activate anti-apoptotic pathways. Science. 305:1163–1167.
2004.PubMed/NCBI
|
|
20
|
Nyati MK, Morgan MA, Feng FY and Lawrence
TS: Integration of EGFR inhibitors with radiochemotherapy. Nat Rev
Cancer. 6:876–885. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sorkin A and Goh LK: Endocytosis and
intracellular trafficking of ErbBs. Exp Cell Res. 315:683–696.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Citri A and Yarden Y: EGF-ERBB signalling:
towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yarden Y: The EGFR family and its ligands
in human cancer: signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morgan S and Grandis JR: ErbB receptors in
the biology and pathology of the aerodigestive tract. Exp Cell Res.
315:572–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goel S, Hidalgo M and Perez-Soler R: EGFR
inhibitor-mediated apoptosis in solid tumors. J Exp Ther Oncol.
6:305–320. 2007.PubMed/NCBI
|
|
27
|
Tice DA, Biscardi JS, Nickles AL and
Parsons SJ: Mechanism of biological synergy between cellular Src
and epidermal growth factor receptor. Proc Natl Acad Sci USA.
96:1415–1420. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gotoh N, Tojo A, Hino M, Yazaki Y and
Shibuya M: A highly conserved tyrosine residue at codon 845 within
the kinase domain is not required for the transforming activity of
human epidermal growth factor receptor. Biochem Biophys Res Commun.
186:768–774. 1992. View Article : Google Scholar
|
